Inovalon Results Presentation Deck
Expanding Patient Analytical Months (PAM)
inovalon
As of June 30th, 2016, Inovalon's Patient Analytical Months (PAM) metric, which tracks the number of
analytical processes that the Company runs on patients, continued to show strong growth, increasing to
approximately 24.3 billion. The Company sees PAM as a strong indicator of the market's demand for our
analytics and the value they deliver.
Billions
25
20
15
10
5
0
Q2 2013 Q3 2013 Q4 2013 Q1 2014 Q2 2014 Q3 2014
Numbers are increasing at a rate of approximately 6.1% compounding quarterly, or 26.9% annually
Please refer to PAM definition in the Company's SEC filings.
INOV 02 2016 Eamings Presentation Supplement (8.3.16) v1.0.0
Q4 2014
5
Q1 2015 Q2 2015 Q3 2015
Q4 2015
Q1 2016 Q2 2016
© 2016 by Inovalon. All rights reserved.View entire presentation